About Protein adenylyltransferase FICD
Protein adenylyltransferase FICD (FICD) is a protein
from Homo sapiens identified by UniProt accession
Q9BVA6, 458 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | Protein adenylyltransferase FICD |
| UniProt accession | Q9BVA6 |
| Gene | FICD |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (15)
Diseases linked to this target (Open Targets).
- Neurodevelopmental delay · score 0.23
- Neonatal insulin-dependent diabetes mellitus · score 0.23
- smoking status measurement · score 0.12
- refractive error measurement · score 0.08
- blood phosphate measurement · score 0.04
- Abnormality of refraction · score 0.02
- pituitary cancer · score 0.00
- psoriasis · score 0.00
- proteostasis deficiencies · score 0.00
- neuropathy · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BVA6-F1 | alphafold | PREDICTED | 83.56 | — |
Amino-acid sequence (458 residues)
MMLIPMASVM AVTEPKWVSV WSRFLWVTLL SMVLGSLLAL LLPLGAVEEQ CLAVLKGLYL LRSKPDRAQH AATKCTSPST ELSITSRGAT LLVAKTKASP AGKLEARAAL NQALEMKRQG KREKAQKLFM HALKMDPDFV DALTEFGIFS EEDKDIIQAD YLYTRALTIS PYHEKALVNR DRTLPLVEEI DQRYFSIIDS KVKKVMSIPK GNSALRRVME ETYYHHIYHT VAIEGNTLTL SEIRHILETR YAVPGKSLEE QNEVIGMHAA MKYINTTLVS RIGSVTISDV LEIHRRVLGY VDPVEAGRFR TTQVLVGHHI PPHPQDVEKQ MQEFVQWLNS EEAMNLHPVE FAALAHYKLV YIHPFIDGNG RTSRLLMNLI LMQAGYPPIT IRKEQRSDYY HVLEAANEGD VRPFIRFIAK CTETTLDTLL FATTEYSVAL PEAQPNHSGF KETLPVKP
Explore Protein adenylyltransferase FICD with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets